Back to Interventions
Substance / Medication

Palifermin

SNOMED 417550009UMLS C0677829

Overview

Active Ingredient
palifermin
RxNorm CUI
196319
Labeler: Swedish Orphan Biovitrum AB (publ)Updated: 2025-12-17T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
A meta-analysis of palifermin efficacy for the management of oral mucositis in patients with solid tumours and haematological malignancy.
Coutsouvelis John, Corallo Carmela, Spencer Andrew et al. · Crit Rev Oncol Hematol · 2022
PMID: 35101586Meta-Analysis
Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin.
Yang Bing-Bing, Gillespie Brad, Smith Brian et al. · J Clin Pharmacol · 2015
PMID: 25880826RCT
A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.
Jacobson Jeffrey M, Wang Hongying, Bordi Rebeka et al. · J Acquir Immune Defic Syndr · 2014
PMID: 24815851RCTFull text (PMC)
Gut protection by palifermin during autologous haematopoietic SCT.
Johansson J-E, Hasséus B, Johansson P et al. · Bone Marrow Transplant · 2009
PMID: 19043460RCT
Pharmacokinetics, pharmacodynamics, and safety assessment of palifermin (rHuKGF) in healthy volunteers.
Zia-Amirhosseini Parnian, Salfi Margaret, Leese Philip et al. · Clin Pharmacol Ther · 2006
PMID: 16765144RCT
Efficacy and safety of keratinocyte growth factor (palifermin) for prevention of oral mucositis in TBI-based allogeneic hematopoietic stem cell transplantation.
Schmidt Volker, Niederwieser Dietger, Schenk Thomas et al. · Bone Marrow Transplant · 2018
PMID: 29545592Observational
Reliability and efficacy of palifermin in prevention and management of oral mucositis in patients with acute lymphoblastic leukemia: a randomized, double-blind controlled clinical trial.
Lucchese Alessandra, Matarese Giovanni, Manuelli Maurizio et al. · Minerva Stomatol · 2016
PMID: 26862696Observational
A prospective study of incidence, clinical and quality of life consequences of oral mucositis post palifermin prophylaxis in patients undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Sakellari Ioanna, Angelopoulou Maria, Tsopra Olga et al. · Ann Hematol · 2015
PMID: 26141369Observational
A randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukaemia.
Bradstock Kenneth F, Link Emma, Collins Marnie et al. · Br J Haematol · 2014
PMID: 25142189Observational
Clinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control study.
Lauritano Dorina, Petruzzi Massimo, Di Stasio Dario et al. · Int J Oral Sci · 2014
PMID: 24357856ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Palifermin (substance)
SNOMED CT
417550009
UMLS CUI
C0677829
RxNorm CUI
196319
Labeler
Swedish Orphan Biovitrum AB (publ)

Clinical Data

This intervention maps to 0 entities in the Healos knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.